Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Argenx Se (DE:1AEA)
FRANKFURT:1AEA
Holding DE:1AEA?
Track your performance easily
1AEA Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€318.00 - €600.00
Previous Close€595
Volume0.00
Average Volume (3M)6.00
Market Cap
€36.21B
Enterprise Value€34.28B
Total Cash (Recent Filing)$2.05B
Total Debt (Recent Filing)$20.00M
Price to Earnings (P/E)―
Beta-0.10
Next Earnings
Feb 27, 2025EPS Estimate
€1.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.23
Shares Outstanding59,194,488
10 Day Avg. Volume0
30 Day Avg. Volume6
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)8.60
Price to Sales (P/S)91.09
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue160.79
Enterprise Value/Gross Profit30.92
Enterprise Value/Ebitda-75.16
Forecast
1Y Price Target
€653.84Price Target Upside9.89% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering23
Argenx Se News
PremiumCompany Announcements
Argenx SE Boosts Myositis Treatment Development
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessThe ongoing Ph2/3 ALKIVIA study of subcutaneous efgartigimod in myositis has met its primary Phase 2 endpoint, resulting in a 'Go' decision to advance clinical development for the Phase 3 program across all three subtypes of myositis studied.
Financial PerformanceVyvgart revenue of $573MM surged past the $555MM estimate, indicating strong sales performance.
Product LaunchThe anticipated launch of the pre-filled syringe is expected to support expansion by enabling patient self-administration.
Bears Say
Competitive LandscapeThere are several bigger questions surrounding Argenx, such as the impact of upcoming data from competitors like Roche, which need to be closely monitored.
Safety ConcernsSafety concerns include numerical albumin drops and LDL increases with 15 mg/kg Q2W nipocalimab, which have not been seen with Vyvgart.
ValuationARGX's valuation has gotten a bit ahead of itself.
---
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
21.85% Mutual Funds
24.94% Other Institutional Investors
51.66% Public Companies and
Individual Investors
1AEA FAQ
What was Argenx Se’s price range in the past 12 months?
Argenx Se lowest stock price was €318.00 and its highest was €600.00 in the past 12 months.
What is Argenx Se’s market cap?
Currently, no data Available
When is Argenx Se’s upcoming earnings report date?
Argenx Se’s upcoming earnings report date is Feb 27, 2025 which is in 67 days.
How were Argenx Se’s earnings last quarter?
Argenx Se released its earnings results on Oct 31, 2024. The company reported €1.324 earnings per share for the quarter, beating the consensus estimate of €0.14 by €1.184.
Is Argenx Se overvalued?
According to Wall Street analysts Argenx Se’s price is currently Undervalued.
Does Argenx Se pay dividends?
Argenx Se does not currently pay dividends.
What is Argenx Se’s EPS estimate?
Argenx Se’s EPS estimate is €1.16.
How many shares outstanding does Argenx Se have?
Argenx Se has 60,367,650 shares outstanding.
What happened to Argenx Se’s price movement after its last earnings report?
Argenx Se reported an EPS of €1.324 in its last earnings report, beating expectations of €0.14. Following the earnings report the stock price went up 2.97%.
Which hedge fund is a major shareholder of Argenx Se?
Among the largest hedge funds holding Argenx Se’s share is Perceptive Advisors LLC. It holds Argenx Se’s shares valued at 64M.
---
Argenx Se Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€653.84 (9.89% Upside)
€653.84 (9.89% Upside)
Blogger Sentiment
Bullish
DE:1AEA Sentiment 100%
Sector Average 70%
Sector Average 70%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
84.06%
12-Months-Change
Fundamentals
Return on Equity
-5.75%
Trailing 12-Months
Asset Growth
50.18%
Trailing 12-Months
Company Description
Argenx Se
argenx SE is a clinical-stage biotechnology company, which engages in the development of antibody-based therapies for the treatment of autoimmune diseases and cancer. Its products include ARGX-113 for the treatment of autoimmune disease myasthenia gravis and ARGX-110 for the treatment of hematological cancer acute myeloid leukemia. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren on April 25, 2008 and is headquartered in Breda, the Netherlands.
---
1AEA Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a strong financial performance with record-breaking revenue growth and successful product launches, particularly in the CIDP segment. However, challenges such as increased operating expenses and the discontinuation of efgartigimod in MN slightly offset the positive aspects. Overall, the company shows strong momentum and a solid financial position.Read More>---
1AEA Stock 12 Month Forecast
Average Price Target
€653.84
▲(9.89% Upside)
Technical Analysis
Best Analysts Covering 1AEA
1 Year
1 Year Success Rate
19/20 ratings generated profit
1 Year Average Return
+27.59%
assigned a buy rating 13 days ago
Copying Allison Bratzel's trades and holding each position for 1 Year would result in 95.00% of your transactions generating a profit, with an average return of +27.59% per trade.
---